Results
Retatrutide Reported Results
Efficacy and tolerability endpoints as reported in trial publications and sponsor disclosures. Values appear here only once verified against their source document.
Efficacy
Latest Verified Phase 3 Result
TRIUMPH-2 · NCT05929079
-20.8%
Mean change in body weight
Retatrutide 12 mg · 80 weeks · Adults with type 2 diabetes and obesity or overweight · Efficacy estimand
What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
Results Explorer
Retatrutide Results Explorer
Filter verified efficacy endpoints by trial, dose, endpoint and treatment duration. Only values verified against an official source document are shown.
Results from different trials should not be compared directly because populations, study designs, treatment durations, endpoints and analysis methods may differ.
Showing 29 of 29 verified results
Download all verified results (CSV)TRIUMPH-2NCT05929079
Change in A1C from baseline
-1.5 percentage points
- Dose
- 12 mg
- Duration
- 80 weeks
- Population
- Adults with type 2 diabetes and obesity or overweight
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-2NCT05929079
Change in A1C from baseline
-1.6 percentage points
- Dose
- 9 mg
- Duration
- 80 weeks
- Population
- Adults with type 2 diabetes and obesity or overweight
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-2NCT05929079
Change in A1C from baseline
-1.4 percentage points
- Dose
- 4 mg
- Duration
- 80 weeks
- Population
- Adults with type 2 diabetes and obesity or overweight
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-2NCT05929079
Change in A1C from baseline
-0.2 percentage points
- Dose
- Placebo
- Duration
- 80 weeks
- Population
- Adults with type 2 diabetes and obesity or overweight
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-2NCT05929079
Mean change in body weight
-20.8%
- Dose
- 12 mg
- Duration
- 80 weeks
- Population
- Adults with type 2 diabetes and obesity or overweight
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-2NCT05929079
Mean change in body weight
-19.1%
- Dose
- 9 mg
- Duration
- 80 weeks
- Population
- Adults with type 2 diabetes and obesity or overweight
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-2NCT05929079
Mean change in body weight
-12.7%
- Dose
- 4 mg
- Duration
- 80 weeks
- Population
- Adults with type 2 diabetes and obesity or overweight
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-2NCT05929079
Mean change in body weight
-4%
- Dose
- Placebo
- Duration
- 80 weeks
- Population
- Adults with type 2 diabetes and obesity or overweight
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-3NCT05882045
Mean change in body weight
-22.6%
- Dose
- 12 mg
- Duration
- 80 weeks
- Population
- Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-3NCT05882045
Mean change in body weight
-21.6%
- Dose
- 9 mg
- Duration
- 80 weeks
- Population
- Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-3NCT05882045
Mean change in body weight
-3.2%
- Dose
- Placebo
- Duration
- 80 weeks
- Population
- Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-1NCT05929066
Mean change in body weight
-28.3%
- Dose
- 12 mg
- Duration
- 80 weeks
- Population
- Adults with obesity or overweight without diabetes
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-1NCT05929066
Mean change in body weight
-25.9%
- Dose
- 9 mg
- Duration
- 80 weeks
- Population
- Adults with obesity or overweight without diabetes
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-1NCT05929066
Mean change in body weight
-19%
- Dose
- 4 mg
- Duration
- 80 weeks
- Population
- Adults with obesity or overweight without diabetes
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-1NCT05929066
Mean change in body weight
-2.2%
- Dose
- Placebo
- Duration
- 80 weeks
- Population
- Adults with obesity or overweight without diabetes
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1NCT06354660
Change in A1C from baseline
-1.9 percentage points
- Dose
- 12 mg
- Duration
- 40 weeks
- Population
- Adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1NCT06354660
Change in A1C from baseline
-2 percentage points
- Dose
- 9 mg
- Duration
- 40 weeks
- Population
- Adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1NCT06354660
Change in A1C from baseline
-1.7 percentage points
- Dose
- 4 mg
- Duration
- 40 weeks
- Population
- Adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1NCT06354660
Change in A1C from baseline
-0.8 percentage points
- Dose
- Placebo
- Duration
- 40 weeks
- Population
- Adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1NCT06354660
Mean change in body weight
-16.8%
- Dose
- 12 mg
- Duration
- 40 weeks
- Population
- Adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1NCT06354660
Mean change in body weight
-15.5%
- Dose
- 9 mg
- Duration
- 40 weeks
- Population
- Adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1NCT06354660
Mean change in body weight
-11.5%
- Dose
- 4 mg
- Duration
- 40 weeks
- Population
- Adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1NCT06354660
Mean change in body weight
-2.5%
- Dose
- Placebo
- Duration
- 40 weeks
- Population
- Adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Estimand
- Efficacy estimand
Peer-reviewed Phase 3What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-4NCT05931367
Change in WOMAC pain score (baseline 6.0)
-4.4 points
- Dose
- 12 mg
- Duration
- 68 weeks
- Population
- Adults with obesity or overweight and knee osteoarthritis without diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Change in WOMAC pain score (baseline 6.0)
-4.5 points
- Dose
- 9 mg
- Duration
- 68 weeks
- Population
- Adults with obesity or overweight and knee osteoarthritis without diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Change in WOMAC pain score (baseline 6.0)
-2.4 points
- Dose
- Placebo
- Duration
- 68 weeks
- Population
- Adults with obesity or overweight and knee osteoarthritis without diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Mean change in body weight
-28.7%
- Dose
- 12 mg
- Duration
- 68 weeks
- Population
- Adults with obesity or overweight and knee osteoarthritis without diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Mean change in body weight
-26.4%
- Dose
- 9 mg
- Duration
- 68 weeks
- Population
- Adults with obesity or overweight and knee osteoarthritis without diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-4NCT05931367
Mean change in body weight
-2.1%
- Dose
- Placebo
- Duration
- 68 weeks
- Population
- Adults with obesity or overweight and knee osteoarthritis without diabetes
- Estimand
- Efficacy estimand
Sponsor topline resultWhat this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
| Trial | Endpoint | Dose | Duration | Population | Estimand | Value | Source |
|---|---|---|---|---|---|---|---|
| TRIUMPH-2NCT05929079 | Change in A1C from baseline | 12 mg | 80 weeks | Adults with type 2 diabetes and obesity or overweight | Efficacy estimand | -1.5 percentage points | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-2NCT05929079 | Change in A1C from baseline | 9 mg | 80 weeks | Adults with type 2 diabetes and obesity or overweight | Efficacy estimand | -1.6 percentage points | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-2NCT05929079 | Change in A1C from baseline | 4 mg | 80 weeks | Adults with type 2 diabetes and obesity or overweight | Efficacy estimand | -1.4 percentage points | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-2NCT05929079 | Change in A1C from baseline | Placebo | 80 weeks | Adults with type 2 diabetes and obesity or overweight | Efficacy estimand | -0.2 percentage points | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-2NCT05929079 | Mean change in body weight | 12 mg | 80 weeks | Adults with type 2 diabetes and obesity or overweight | Efficacy estimand | -20.8% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-2NCT05929079 | Mean change in body weight | 9 mg | 80 weeks | Adults with type 2 diabetes and obesity or overweight | Efficacy estimand | -19.1% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-2NCT05929079 | Mean change in body weight | 4 mg | 80 weeks | Adults with type 2 diabetes and obesity or overweight | Efficacy estimand | -12.7% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-2NCT05929079 | Mean change in body weight | Placebo | 80 weeks | Adults with type 2 diabetes and obesity or overweight | Efficacy estimand | -4% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-3NCT05882045 | Mean change in body weight | 12 mg | 80 weeks | Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes | Efficacy estimand | -22.6% | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
| TRIUMPH-3NCT05882045 | Mean change in body weight | 9 mg | 80 weeks | Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes | Efficacy estimand | -21.6% | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
| TRIUMPH-3NCT05882045 | Mean change in body weight | Placebo | 80 weeks | Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes | Efficacy estimand | -3.2% | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
| TRIUMPH-1NCT05929066 | Mean change in body weight | 12 mg | 80 weeks | Adults with obesity or overweight without diabetes | Efficacy estimand | -28.3% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-1NCT05929066 | Mean change in body weight | 9 mg | 80 weeks | Adults with obesity or overweight without diabetes | Efficacy estimand | -25.9% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-1NCT05929066 | Mean change in body weight | 4 mg | 80 weeks | Adults with obesity or overweight without diabetes | Efficacy estimand | -19% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-1NCT05929066 | Mean change in body weight | Placebo | 80 weeks | Adults with obesity or overweight without diabetes | Efficacy estimand | -2.2% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRANSCEND-T2D-1NCT06354660 | Change in A1C from baseline | 12 mg | 40 weeks | Adults with type 2 diabetes inadequately controlled by diet and exercise alone | Efficacy estimand | -1.9 percentage points | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRANSCEND-T2D-1NCT06354660 | Change in A1C from baseline | 9 mg | 40 weeks | Adults with type 2 diabetes inadequately controlled by diet and exercise alone | Efficacy estimand | -2 percentage points | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRANSCEND-T2D-1NCT06354660 | Change in A1C from baseline | 4 mg | 40 weeks | Adults with type 2 diabetes inadequately controlled by diet and exercise alone | Efficacy estimand | -1.7 percentage points | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRANSCEND-T2D-1NCT06354660 | Change in A1C from baseline | Placebo | 40 weeks | Adults with type 2 diabetes inadequately controlled by diet and exercise alone | Efficacy estimand | -0.8 percentage points | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRANSCEND-T2D-1NCT06354660 | Mean change in body weight | 12 mg | 40 weeks | Adults with type 2 diabetes inadequately controlled by diet and exercise alone | Efficacy estimand | -16.8% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRANSCEND-T2D-1NCT06354660 | Mean change in body weight | 9 mg | 40 weeks | Adults with type 2 diabetes inadequately controlled by diet and exercise alone | Efficacy estimand | -15.5% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRANSCEND-T2D-1NCT06354660 | Mean change in body weight | 4 mg | 40 weeks | Adults with type 2 diabetes inadequately controlled by diet and exercise alone | Efficacy estimand | -11.5% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRANSCEND-T2D-1NCT06354660 | Mean change in body weight | Placebo | 40 weeks | Adults with type 2 diabetes inadequately controlled by diet and exercise alone | Efficacy estimand | -2.5% | Peer-reviewed Phase 3 What this meansA verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication. Figure / record sourceLast verified 30 Sept 2026 Peer-reviewed publicationLast verified 13 Oct 2026 |
| TRIUMPH-4NCT05931367 | Change in WOMAC pain score (baseline 6.0) | 12 mg | 68 weeks | Adults with obesity or overweight and knee osteoarthritis without diabetes | Efficacy estimand | -4.4 points | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
| TRIUMPH-4NCT05931367 | Change in WOMAC pain score (baseline 6.0) | 9 mg | 68 weeks | Adults with obesity or overweight and knee osteoarthritis without diabetes | Efficacy estimand | -4.5 points | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
| TRIUMPH-4NCT05931367 | Change in WOMAC pain score (baseline 6.0) | Placebo | 68 weeks | Adults with obesity or overweight and knee osteoarthritis without diabetes | Efficacy estimand | -2.4 points | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
| TRIUMPH-4NCT05931367 | Mean change in body weight | 12 mg | 68 weeks | Adults with obesity or overweight and knee osteoarthritis without diabetes | Efficacy estimand | -28.7% | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
| TRIUMPH-4NCT05931367 | Mean change in body weight | 9 mg | 68 weeks | Adults with obesity or overweight and knee osteoarthritis without diabetes | Efficacy estimand | -26.4% | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
| TRIUMPH-4NCT05931367 | Mean change in body weight | Placebo | 68 weeks | Adults with obesity or overweight and knee osteoarthritis without diabetes | Efficacy estimand | -2.1% | Sponsor topline result What this meansThe sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records. Figure / record sourceLast verified 30 Sept 2026 |
Weekly Briefing
The Retatrutide Report
The most important retatrutide developments, once a week.
- Clinical trial changes
- New PubMed research
- FDA / EMA regulatory developments
- Eli Lilly announcements
- Major efficacy and safety updates
No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.